Clinical trials: IPMN, Pancreatic, open to volunteers
IPMN, IPMN, Pancreatic
Impact of GLP-1 Receptor Agonists on Patients With IPMN
This study investigates the impact of GLP-1 receptor agonists (GLP-1 RAs) on patients with intraductal papillary mucinous neoplasms (IPMNs), a type of pancreatic cystic neoplasm that can progress to malignancy.
- Conditions
- IPMN, IPMN, Pancreatic, GLP-1, Intraductal Papillary Mucinous Neoplasm of Pancreas
- Trial name
- IPMN-GLP1RA (NCT07014709)
- Testing
- GLP1 receptor agonist
- Where
- Switzerland
- Volunteers
- 30 people
- Sponsor
- Hôpital Fribourgeois
Pancreas Head Cancer, Pancreas Adenocarcinoma
Preventing Postoperative Complications in Patients Undergoing High-risk Pancreatoduodenectomy With a Bundle Approach Including Hydrocortisone, Octreotide, and the Teres Ligament Patch (PANENCA)
The PANENCA trial aims to reduce postoperative complications in patients undergoing pancreatoduodenectomy (also known as a Whipple procedure), a complex surgical operation performed to remove tumors located in or near the head of…
- Conditions
- Pancreas Head Cancer, Pancreas Adenocarcinoma, IPMN, Pancreatic, Cholangio Carcinoma
- Trial name
- PANENCA (NCT07262957)
- Testing
- HOP bundle
- Where
- Netherlands
- Volunteers
- 400 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
PAPILLARY AND MUCINOUS INTRACANAL TUMORS OF THE PANCREAS
Early Detection of Pancreatic Cancer in Patients With Papillary and Mucinous Intracanal Tumours of the Pancreas Papillary and Mucinous Tumours of the Pancreas
This trial is a prospective, exploratory and descriptive study. The primary objective is to identify early diagnostic biomarkers in patients with TIPMP based on the analysis of Treg lymphocyte subpopulations and epigenetic…
- Trial name
- NCT06000553
- Testing
- blood sampling at inclusion, 6 months, 1 year and 2 years. Tumor and intracystic fluid samples are taken only if a biopsy is planned following MRI results.
- Volunteers
- 360 people
- Sponsor
- Institut Paoli-Calmettes
IPMN, Pancreatic Cancer
Surveillance Discontinuation in 5 Year Stable Trivial Branch Duct Intraductal Papillary Mucinous Neoplasms
BACKGROUND: Patients with trivial branch duct intraductal papillary mucinous neoplasm (BD IPMN) which remain s stable over 5 years reportedly do not have an increased risk of developing pancreatic cancer (PC) compared to the…
- Trial name
- TRIVIAL (NCT07056972)
- Testing
- Discontinuation of surveillance
- Volunteers
- 394 people, healthy volunteers welcome
- Sponsor
- Azienda Ospedaliera di Padova
Intraductal Papillary Mucinous Neoplasm of Pancreas
Feasibility Trial of EUS-PCA in IPMN Pancreatic Cysts
The goal of this single-arm intervention trial is to determine the feasibility of implementing endoscopic ultrasound-guided pancreatic cyst chemoablation (EUS-PCA) using gemcitabine and paclitaxel for intraductal papillary…
- Trial name
- NCT06162468
- Testing
- Endoscopic ultrasound-guided pancreatic cyst chemoablation (EUS-PCA) using gemcitabine and paclitaxel
- Where
- 2 sites in New Zealand
- Volunteers
- 20 people
- Sponsor
- University of Auckland, New Zealand
IPMN, Pancreatic
Integration of Multiomics Markers for Invasive IPMNs Identification Through the Set-up of the INvasive Cyst bIomarkers Detection (INCITE) Consortium
Although intraductal papillary mucinous neoplasms (IPMNs) represent potential precursors of pancreatic cancer, IPMNs with invasive cancer are rare.
- Trial name
- INCITE (NCT06694792)
- Where
- Italy
- Volunteers
- 800 people
- Sponsor
- IRCCS San Raffaele
Pancreatic Cyst
Confocal Laser Endomicroscopy as an Imaging Biomarker for the Diagnosis of Pancreatic Cystic Lesions
The study schema is shown in Figure 4. (A) All patients referred to one of the participating academic centers for EUS evaluation of the PCL will be enrolled in the protocol if they satisfy inclusion criteria.
- Trial name
- CLIMB (NCT03492151)
- Where
- 10 sites in United States
- Volunteers
- 500 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer (CRC)
Advanced Therapies for Liver Metastases
Liver metastases (MTS) are the main cause of death for patients affected by colorectal carcinoma (CRC) and pancreatic ductal adenocarcinoma (PDAC), thus representing the major unmet clinical need for these malignancies.
- Conditions
- Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer (CRC), Liver Metastasis, IPMN, Pancreatic
- Trial name
- LiMeT (NCT04622423)
- Where
- Italy
- Volunteers
- 625 people, healthy volunteers welcome
- Sponsor
- IRCCS San Raffaele
IPMN, Pancreatic, IPMN
Intraductal Papillary Mucinous Neoplasm (IPMN) Database - A Tool to Predict Pancreatic Cancer
Pancreatic cancer is the 5th leading cause of cancer death in Australia. Surgery remains the most effective treatment for early pancreatic cancer and currently the only potential for cure.
- Trial name
- MAPS (NCT05117723)
- Where
- Australia
- Volunteers
- 1,000 people
- Sponsor
- St Vincent's Hospital Melbourne
Pancreatic Cancer, Chronic Pancreatitis
Diagnostic Utility of Protein Biomarkers in Pancreatic Ductal Adenocarcinoma
The goal of this prospective multicenter observational study is to evaluate the diagnostic accuracy of blood-based protein biomarkers for detecting pancreatic ductal adenocarcinoma (PDAC) in adults aged 18 years and older.
- Conditions
- Pancreatic Cancer, Chronic Pancreatitis, Intraductal Papillary Mucinous Neoplasm, Mucinous Cystic Neoplasm
- Trial name
- NCT07875582
- Testing
- Blood-Based Protein Biomarker Assessment
- Where
- Romania
- Volunteers
- 100 people
- Sponsor
- Grigore T. Popa University of Medicine and Pharmacy
IPMN, Pancreatic, Pancreatic Cancer, Resected
Venous Resection in Patients Undergoing Pancreatic Surgery
Pancreatic surgery is the only treatment in the multimodality approach to pancreatic cancer sine qua non long-term survival cannot be achieved.
- Conditions
- IPMN, Pancreatic, Pancreatic Cancer, Resected, Pancreatic Cancer Borderline, Chronic Pancreatitis
- Trial name
- VENUS (NCT07621029)
- Where
- 2 sites in Netherlands, Sweden
- Volunteers
- 1,000 people
- Sponsor
- Sahlgrenska University Hospital
Intraductal Papillary Mucinous Neoplasms, Pancreatic Exocrine Insufficiency
IPEX Study: Pancreatic Exocrine Insufficiency as a Functional Marker of Disease Progression in Patients With IPMN
Intraductal Papillary Mucinous Neoplasms (IPMN) are pancreatic cystic neoplasms managed through imaging-based surveillance focused on oncologic risk.
- Trial name
- IPEX (NCT07535125)
- Volunteers
- 600 people
- Sponsor
- A.O.U. Città della Salute e della Scienza
Pancreatic Cancer, IPMN, Pancreatic
Pancreatic Cancer Initial Detection Via Liquid Biopsy
The overall rationale of PANCAID is to provide a diagnostic blood test for early diagnosis of pancreatic cancer. With a set of different liquid biopsy methods, it is the aim to measure these markers in well-defined patient…
- Conditions
- Pancreatic Cancer, IPMN, Pancreatic, Individuals at Risk, Chronic Pancreatitis
- Trial name
- PANCAID (NCT06283576)
- Testing
- Liquid biopsy
- Where
- Sweden
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Karolinska University Hospital
Pancreatic Carcinoma, Pancreatic Intraductal Papillary Mucinous Neoplasm, Pancreatobiliary-Type
Ultra-High Resolution Optical Coherence Tomography in Detecting Micrometer Sized Early Stage Pancreatic Cancer in Participants With Pancreatic Cancer
This trial studies how well ultra-high resolution optical coherence tomography works in detecting micrometer sized early stage pancreatic cancer in participants with pancreatic cancer.
- Trial name
- NCT03711890
- Testing
- Optical Coherence Tomography, Therapeutic Conventional Surgery, Laboratory Evaluation
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Intraductal Papillary Mucinous Neoplasm of Pancreas, Pancreatic Neoplasms
Real-Time AI During Pancreatoscopy for Detection of Pancreatic Neoplasia
This prospective pilot study will evaluate the diagnostic performance of a previously validated artificial intelligence (AI) model when applied in real time during digital per-oral pancreatoscopy (POPS).
- Trial name
- NCT07809841
- Testing
- AIWorks-Cholangioscopy Real-Time Artificial Intelligence Model
- Where
- Ecuador
- Volunteers
- 60 people
- Sponsor
- Instituto Ecuatoriano de Enfermedades Digestivas
Pancreatic Ductal Adenocarcinoma (PDAC), Intraductal Papillary Mucinous Neoplasm of Pancreas
Predictive Biomarkers for Early Diagnosis of Pancreatic Ductal Adenocarcinoma (PDAC)
Pancreatic ductal adenocarcinoma (PDAC) is one of the cancers with the poorest prognosis and is often diagnosed at an advanced stage, resulting in very low 5-year survival rates.
- Conditions
- Pancreatic Ductal Adenocarcinoma (PDAC), Intraductal Papillary Mucinous Neoplasm of Pancreas, Pancreatic Intraepithelial Neoplasia
- Trial name
- B-PDAC (NCT07709052)
- Volunteers
- 180 people
- Sponsor
- Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis
Intraductal Papillary Mucinous Neoplasm
Exploring Biomarkers of the Carcinogenesis of Intraductal Papillary Mucinous Neoplasm (IPMN) of the Pancreas
This is a prospective, open large cohort study to explore biomarkers for detecting early carcinogenesis of IPMN.
- Trial name
- NCT05433935
- Testing
- Observation
- Where
- China
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Zhejiang University
Intraductal Papillary Mucinous Neoplasm of Pancreas, Pancreatic Cyst
Endocrine, Metabolic, Inflammatory Biomarkers to Identify Highgrade Dysplasia/invasive Carcinoma in Patients with IPMN of the Pancreas
Under the hypotheses that a more accurate patients selection could limit the problem of overtreatment and that benign intraductal papillary mucinous neoplasms (IPMN) have a distinguishable Endocrine/Metabolic/Inflammatory (EMI)…
- Trial name
- EMI-IPMN (NCT06706700)
- Where
- Italy
- Volunteers
- 586 people
- Sponsor
- IRCCS San Raffaele
Motor Function, Cognitive Function
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
This study is a postmarketing requirement jointly carried out by four NDA holders (Bayer AG, Bracco, GE Healthcare and Guerbet) and the CRO IQVIA.
- Conditions
- Motor Function, Cognitive Function, Contrast Media
- Trial name
- ODYSSEY (NCT04373564)
- Testing
- Motor Tests, Cognitive Tests, Unenhanced-MRI of the brain
- Where
- 51 sites in United States, Brazil and 6 more
- Volunteers
- 2,076 people
- Sponsor
- Guerbet
IPMN, Pancreatic, Pancreas Cancer
The LINFU® U.S. Registry in Patients With IPMN (Intraductal Papillary Mucinous Neoplasm of the Pancreas)
In this study, LINFU® will be evaluated in patients who have been identified with IPMN to determine if it can be used to help identify early, pancreatic ductal adenocarcinoma and its noninvasive precursor lesions (dysplasia).
- Conditions
- IPMN, Pancreatic, Pancreas Cancer, Pancreatic Cyst
- Trial name
- NCT06276764
- Testing
- LINFU®
- Where
- United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Adenocyte, LLC